Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Анемия при хронической болезни почек

Список литературы

  1. Van Wyck D.B. et al. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease (2012) [Electronic resource]. 2012. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., Suppl. 2012; 2
  2. National Collaborating Centre for Chronic Conditions (UK). Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children [Electronic resource]. 2006. URL: https://pubmed.ncbi.nlm.nih.gov/20945579/ (accessed: 20.07.2020).
  3. McMurray J.J. V. et al. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease // Kidney Int. Suppl. 2012. Vol. 2, № 4. P. 279–331.
  4. Мак-Дугалл И., пер. с англ под ред. Котенко О.Н. Карманный справочник по нефрогенной анемии. М.: ГЭОТАР_Медиа, 2015
  5. Kimachi M. et al. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients// Nephron 2015.131: 123-130 Doi:10.1159/000438870
  6. Шило В.Ю., Земченков А.Ю., Гуревич К.Я., Добронравов В.А., Лысенко (Козловская) Л.В., Ермоленко В.М., Смирнов А.В., Томилина Н.А., Хасабов Н.Н., Шилов Е.М., Шостка Г.Д. Российские национальные рекомендации по диагностике и лечению анемии при хронической болезни почек. Нефрология и диализ. 2016;18(1):19-34.
  7. Koulouridis I., et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013. 61(1): 44-56.
  8. Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-Медиа, 2011. 304 p.
  9. Van Wyck D.B. et al. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target [Electronic resource]. 2007.
  10. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. / ed. Поддубной И.В., Савченко В.Г. Москва, 2018. 213–241 p.
  11. Rajkumar S.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, № 12. P. e538–e548.
  12. Misra A. et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma // Indian Journal of Hematology and Blood Transfusion. Springer India, 2016. Vol. 32, № 1. P. 10–17.
  13. Julie D. et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma // Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e117.
  14. Hill Q, Stamps R, Massey E et al. Thе diagnosis and management of primary autoimmune haemolitic anamia Br J Haematol 2017; 176:395—411.
  15. Shutov E et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not ondialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol DialTransplant. 2021. Epub 2021/02/26. pmid:33630072
  16. Yap, DYH et al. Recommendations by the Asian Pacific society of nephrology (APSN) on theappropriate use of HIF-PH inhibitors. Nephrology. 2021; 26: 105– 118. p.108. https://doi.org/10.1111/nep.13835
  17. Lei J., Li H., and Wang S. Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients //Hindawi BioMed Research International Volume 2022, Article ID 2413176, 12 pages https://doi.org/10.1155/2022/2413176
  18. Шутов Е.В.. Горелова Е.А., Сороколлетов С.М. Ингибиторы пролилгидроксилазы индуцируемого гипоксией фактора в лечении анемии больных с хронической болезнью почек.Эффективная фармакотерапия 2022.Том 18; №3. Урология и нефрологияю Стр.22-30.
  19. Chonchol M. et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis //Nephrology Dialysis Transplantation. – 2008. – Т. 23. – №. 9. – С. 2879-2883.
  20. Nand N. et al. Role of high-sensitivity C-reactive Protein as a Marker of Inflammation in pre-dialysis patients of chronic renal failure //JIACM. – 2009. – Т. 10. – №. 1. – С. 18-22.
  21. Mikhail A. et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease //BMC nephrology. – 2017. – Т. 18. – С. 1-29.
  22. Mikhail A. et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease //BMC nephrology. – 2017. – Т. 18. – С. 1-29.
  23. Daud W. R. W., Shah S. A., Ali R. A. R. Endoscopic findings among geriatric patients with anaemia and chronic kidney disease at a tertiary teaching hospital in Malaysia //Med J Malaysia. – 2022. – Т. 77. – С. 284-291.
  24. García Agudo R. et al. Gastrointestinal lesions in chronic kidney disease patients with anemia //Nefrología (English Edition). – 2019. – Т. 39. – №. 1. – С. 50-57.
  25. Chonchol M. et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis //Nephrology Dialysis Transplantation. – 2008. – Т. 23. – №. 9. – С. 2879-2883.
  26. Nand N. et al. Role of high-sensitivity C-reactive Protein as a Marker of Inflammation in pre-dialysis patients of chronic renal failure //JIACM. – 2009. – Т. 10. – №. 1. – С. 18-22.
  27. Keshk R. A. et al. Relation between intact parathyroid hormone and hemoglobin level in chronic kidney disease patients on hemodialysis //Tanta Medical Journal. – 2016. – Т. 44. – №. 4. – С. 170-175.
  28. Russo D. et al. Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease //Journal of Nephrology. – 2015. – Т. 28. – С. 701-708.
  29. Cannata J. B. et al. Serum aluminum transport and aluminum uptake in chronic renal failure: role of iron and aluminum metabolism //Nephron. – 1993. – Т. 65. – №. 1. – С. 141-146.
  30. Palmer S. C. et al. Erythropoiesis‐stimulating agents for anaemia in adults with chronic kidney disease: a network meta‐analysis //Cochrane Database of Systematic Reviews. – 2014. – №. 12.
  31. Bruce G., Schulga P., Reynolds B. C. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review //Clinical Kidney Journal. – 2022. – Т. 15. – №. 8. – С. 1483-1505.
  32. Tang M. et al. Safe and effective treatment for anemic patients with chronic kidney disease: an updated systematic review and meta-analysis on roxadustat //Frontiers in pharmacology. – 2021. – Т. 12. – С. 658079.
  33. Qie S. et al. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review //International urology and nephrology. – 2021. – Т. 53. – С. 985-997.
  34. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Vol.105, Issue 4, Suppl. S117 - S314.
  35. Koshy S.M., Geary D.F. Anemia in children with chronic kidney disease // Pediatr. Nephrol. 2008. Vol. 23. P. 209–219.
  36. Kaufman J.S., Reda D.J., Fye C.L. et al. Subcutaneous compared with in travenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients // N. Engl. J. Med. 1998. Vol. 339. P. 578–583.
  37. Пропедевтика внутренних болезней: учебник / Н. А. Мухин, В. С. Моисеев. - 2-е изд., доп. и перераб. - М. : ГЭОТАР-Медиа, 2020. Стр. 519-521

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*